Buynetmeds.com has been sent a warning letter over the sale of opoioids and weight-loss drugs without a prescription.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Find the answer for Org. that regulates Ozempic from the people who brought you the USA TODAY Daily Crossword Puzzle.

Eight weeks. That’s how long it takes, on average, for the pounds to begin creeping back after someone stops taking the world ...

GLP-1 drugs came out in 2005 as a Type 2 diabetes treatment. But in recent years their popularity for weight loss -- and the cost -- has taken off.

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Lawmakers are trying to restore access to GLP-1 weight loss drugs, like Ozempic and Wegovy, after Ohio removed medical ...